DYN
Income statement / Annual
Last year (2023), Dyne Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Dyne Therapeutics, Inc.'s net income was -$235.94 M.
See Dyne Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$506.00 M
|
$1.37 B
|
$842.00 M
|
$1.47 B
|
| Cost of Revenue |
$2.46 M |
$3.35 M |
$1.09 M |
$700,000.00 |
$271,000.00 |
$24,000.00 |
$2.93 B |
$2.28 B |
$2.03 B |
$1.15 B |
| Gross Profit |
-$2.46 M |
-$3.35 M |
-$1.09 M |
-$700,000.00 |
-$271,000.00 |
-$24,000.00 |
-$2.43 B |
-$915.00 M |
-$1.19 B |
$321.00 M |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
-4.79 |
-0.67 |
-1.41 |
0.22 |
| Research and Development
Expenses |
$210.76 M
|
$142.76 M
|
$121.31 M
|
$45.20 M
|
$11.04 M
|
$4.28 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$31.40 M
|
$28.20 M
|
$28.72 M
|
$13.45 M
|
$2.79 M
|
$517,000.00
|
$189.00 M
|
$161.00 M
|
$128.00 M
|
-$97.00 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$31.40 M
|
$28.20 M
|
$28.72 M
|
$13.45 M
|
$2.79 M
|
$517,000.00
|
$189.00 M
|
$161.00 M
|
$128.00 M
|
-$97.00 M
|
| Other Expenses |
$0.00 |
$2.86 M |
-$8,000.00 |
-$790,000.00 |
-$1.32 M |
-$21,000.00 |
$0.00 |
$0.00 |
$0.00 |
-$211.00 M |
| Operating Expenses |
$242.16 M |
$170.96 M |
$150.03 M |
$58.65 M |
$13.83 M |
$4.80 M |
$189.00 M |
$161.00 M |
$128.00 M |
-$308.00 M |
| Cost And Expenses |
$242.16 M |
$170.96 M |
$150.03 M |
$58.65 M |
$13.83 M |
$4.80 M |
$3.12 B |
$2.44 B |
$2.16 B |
$837.00 M |
| Interest Income |
$7.64 M |
$2.92 M |
$742,000.00 |
$56,000.00 |
$290,000.00 |
$5,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$2.92 M |
$0.00 |
$396,000.00 |
$0.00 |
$5,000.00 |
$616.00 M |
$625.00 M |
$546.00 M |
$67.00 M |
| Depreciation &
Amortization |
$1.67 M
|
$3.35 M
|
$1.09 M
|
$700,000.00
|
$271,000.00
|
$24,000.00
|
$867.00 M
|
$766.00 M
|
$614.00 M
|
$292.00 M
|
| EBITDA |
-$233.48 M
|
-$164.75 M
|
-$148.20 M
|
-$58.34 M
|
-$14.59 M
|
-$4.79 M
|
$949.00 M
|
$106.00 M
|
$736.00 M
|
$292.00 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
1.88 |
0.08 |
0.87 |
0.2 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.81
|
-0.47
|
0.08
|
-0.22
|
| Total Other
Income/Expenses Net |
$6.23 M
|
$2.86 M
|
$734,000.00
|
-$790,000.00
|
-$1.03 M
|
-$16,000.00
|
-$126.00 M
|
-$649.00 M
|
-$491.00 M
|
$50.00 M
|
| Income Before Tax |
-$235.94 M |
-$168.10 M |
-$149.29 M |
-$59.44 M |
-$14.86 M |
-$4.81 M |
-$538.00 M |
-$1.29 B |
-$427.00 M |
-$268.00 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
-1.06
|
-0.94
|
-0.51
|
-0.18
|
| Income Tax Expense |
$0.00 |
-$2.86 M |
-$8,000.00 |
-$700,000.00 |
-$1.32 M |
-$11,000.00 |
-$610.00 M |
-$45.00 M |
-$474.00 M |
$117.00 M |
| Net Income |
-$235.94 M |
-$165.24 M |
-$149.28 M |
-$58.74 M |
-$13.54 M |
-$4.81 M |
$76.00 M |
-$1.24 B |
$50.00 M |
-$67.00 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0.15 |
-0.91 |
0.06 |
-0.05 |
| EPS |
-3.95 |
-3.18 |
-2.93 |
-4.08 |
-0.3 |
-0.47 |
0.47 |
-9.61 |
0.4 |
-0.53 |
| EPS Diluted |
-3.95 |
-3.18 |
-2.93 |
-4.08 |
-0.3 |
-0.47 |
0.47 |
-9.61 |
0.4 |
-0.53 |
| Weighted Average Shares
Out |
$59.68 M
|
$51.98 M
|
$50.90 M
|
$14.40 M
|
$45.42 M
|
$10.32 M
|
$162.00 M
|
$129.00 M
|
$125.00 M
|
$126.00 M
|
| Weighted Average Shares
Out Diluted |
$59.68 M
|
$51.98 M
|
$50.90 M
|
$14.40 M
|
$45.42 M
|
$10.32 M
|
$162.00 M
|
$129.00 M
|
$126.00 M
|
$126.00 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
